Skip to content
Menu

PTC Therapeutics, Inc. PTCT

Full chart Compare
Set alert

Price alert · PTCT

All alert types
56.42 USD -1.91 (-3.27%)

Regular-session close

56.42 0.00 0.00%

After hours · Nov 20, 5:31 PM ET

56.18 Day range 58.96
56.18 52-week range 90.87
YTD
-25.72%
1 year
-26.21%

 

No chart data for this range yet.
Market cap
4.71B
Revenue (ttm)
1.16B
Profit margin
-9.17%
EPS (ttm)
-1.47
Shares out
83.54M
Forward P/E
17.69
YTD return
-25.72%
1-year return
-26.21%
50-day average
63.45
200-day average
69.87
Volume
952.60K
Avg volume
1.07M
Open
58.80
Previous close
58.33
Day's range
56.18 – 58.96
52-week range
56.18 – 90.87
Beta
0.51
Analysts
Buy
Price target
100.47 (+78.1%)
Earnings date
Feb 18, 2027

Key statistics

Enterprise value
5.69B
Price / sales
4.08
Revenue growth
69.60%
Free cash flow
159.94M
Total cash
2.13B
Total debt
2.94B
Short % of float
12.62%

Fundamental scorecard

5 of 25 checks passed on PTCT’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PTCT Revenue — quarterly 357.81M
PTCT Net income — quarterly -51.69M
PTCT EPS — quarterly -0.62

Earnings

PTCT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 18, 2027Dec 30, 20260.3468———
Oct 29, 2026Sep 30, 20260.1434-0.62-0.76-532.36%
Jul 30, 2026Jun 30, 20260.23630.92+0.68+289.34%
May 7, 2026Mar 31, 2026-0.45-0.03+0.42+93.33%
Feb 19, 2026Dec 31, 2025-0.21-1.67-1.46-695.24%
Nov 4, 2025Sep 30, 2025-1.190.20+1.39+116.81%

Upgrades / downgrades

PTCT analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026CitigroupmainBuyBuy
Oct 30, 2026TD CowenmainBuyBuy
Oct 30, 2026RBC CapitalmainSector PerformSector Perform
Oct 30, 2026Wells FargomainOverweightOverweight
Oct 8, 2026RBC CapitalmainSector PerformSector Perform
Sep 22, 2026Cantor FitzgeraldmainOverweightOverweight

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
ptcbio.com

News

Your note

Sign in to keep a note on PTCT — it syncs with the Stock Master app.

Insider holders

PTCT insider holders
InsiderRelationLatest transactionDateShares held
ALMSTEAD NEIL GREGORYChief Technology OfficerSaleJul 8, 202663,198
BOULDING MARK ELLIOTTOfficerSaleNov 15, 2026105,272
GOLDEN LEE SCOTTOfficerSaleApr 1, 202679,115
GRAVIER PIERREChief Financial OfficerSaleJul 13, 202683,986
KLEIN MATTHEW BChief Executive OfficerSaleAug 3, 2026383,868
PAUWELS ERICOfficerSaleJun 9, 202673,411

Institution ownership

PTCT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.17.23%14,397,317812.30MSep 29, 2026
Janus Henderson Group Ltd.8.22%6,871,205387.67MSep 29, 2026
State Street Corporation6.60%5,512,555311.02MSep 29, 2026
Wellington Management Group, LLP6.32%5,277,697297.77MSep 29, 2026
Vanguard Portfolio Management LLC5.96%4,978,205280.87MSep 29, 2026
Vanguard Capital Management LLC4.33%3,618,497204.16MSep 29, 2026

Fund ownership

PTCT fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.95%4,971,168280.47MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.15%2,635,817148.71MJun 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund2.77%2,310,268130.35MJul 30, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.62%2,186,953123.39MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.56%2,142,713120.89MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.28%1,902,975107.37MJun 29, 2026